Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch.   OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners.   Windward Bio has […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!